STOCK TITAN

Cue Health Inc. - HLTH STOCK NEWS

Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.

Cue Health Inc. (HLTH) delivers innovative at-home diagnostic solutions through its integrated platform of molecular testing and mobile health technology. This news hub provides investors and stakeholders with essential updates about the company’s financial performance, product developments, and strategic initiatives.

Access timely announcements including quarterly earnings reports, FDA clearances, partnership agreements, and research breakthroughs. Our curated collection ensures you stay informed about HLTH’s advancements in digital health diagnostics without speculative commentary.

Key updates cover regulatory milestones, new test kit approvals, executive leadership changes, and scientific validation studies. Each release maintains focus on verifiable facts about the company’s patented technology and market position.

Bookmark this page for direct access to primary source materials about Cue Health’s progress in transforming personal health monitoring. Check regularly for objective updates on their mobile-integrated diagnostic ecosystem and business developments.

Rhea-AI Summary

Cue Health (Nasdaq: HLTH) announced that its COVID-19 tests can detect the Omicron variant, with 99.2% match to primer sequences. These portable tests deliver lab-quality results in about 20 minutes for users aged 2 and over. The company emphasizes ongoing surveillance for variants, showcasing its commitment to accuracy. Cue's recent collaborations include a study with Helix for public health sequencing and a direct-to-consumer platform launch, enhancing access to testing. Cue's tests have received multiple international authorizations, reinforcing its position in diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
covid-19
-
Rhea-AI Summary

On November 18, 2021, Cue Health (Nasdaq: HLTH) and Helix announced a collaboration to enable individuals who test positive for COVID-19 through Cue's at-home test to identify the specific virus variant. This initiative addresses the ongoing need for viral sequencing, particularly amidst more contagious strains. Participants will receive a sample collection kit, with results shared within ten days via Cue's app. Although not FDA authorized for healthcare use yet, this research aims to enhance understanding of SARS-CoV-2 variants and improve pandemic readiness by contributing to global data sharing initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
covid-19
-
Rhea-AI Summary

Cue Health Inc. (HLTH) reported a record total revenue of $223.7 million for Q3 2021, marking a 63% increase compared to Q2 2021. Public sector revenue grew by 23% to $129.5 million, while private sector revenue surged by 191% to $94.2 million. The product gross margin increased to 60.2%. The company added over 50 new customers, nearly tripling its customer base. Operating expenses rose to $47.7 million, leading to a slight net income decrease to $19.3 million. Cue Health provides a revenue guidance of $580 million to $590 million for the full year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
Rhea-AI Summary

On November 15, 2021, Cue Health (Nasdaq: HLTH) will launch its direct-to-consumer virtual health platform, offering its groundbreaking molecular COVID-19 test via a new eCommerce site and in-app shop. Recognized by organizations like Google and Mayo Clinic, the Cue COVID-19 test is the first FDA-authorized molecular test for at-home use. Cue+ membership provides 24/7 access to certified physicians, same-day product delivery, and CDC-compliant test results. Cue aims to make health management easier and more convenient for individuals, enabling them to monitor and manage their health effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.01%
Tags
covid-19
-
Rhea-AI Summary

On November 1, 2021, Cue Health (Nasdaq: HLTH) announced its partnership with Major League Baseball (MLB) to provide COVID-19 testing solutions during the postseason and World Series. Cue's integrated platform features portable health monitoring systems and FDA-authorized COVID-19 tests, delivering results to mobile devices within 20 minutes. MLB's Vice President praised Cue's technology for enhancing the league's health protocols. Cue Health's diagnostics enable users to manage their health effectively, having previously partnered with organizations like Google and Mayo Clinic for its innovative testing solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
covid-19
-
Rhea-AI Summary

Cue Health Inc. (NASDAQ: HLTH) will release its third quarter 2021 financial results on November 10, 2021. A conference call will be hosted at 1:30 PM PT / 4:30 PM ET to discuss the financials and company highlights. Interested parties can access the call via telephone or watch the live webinar on the company's investor website. Cue Health focuses on healthcare technology, enabling consumers to manage their health information and providing accessible diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
Rhea-AI Summary

On October 14, 2021, Cue Health Inc. (Nasdaq: HLTH) announced its partnership with the NBA as the league's Official Home and Point of Care Test for the 2021-22 season. Cue will provide all 30 teams and referees with its FDA-authorized COVID-19 test, enabling at-home and OTC use without prescription. The Cue Health Monitoring System allows results in about 20 minutes, accessible via mobile devices. Cue previously collaborated with the NBA during the 2020 season, introducing regular testing protocols. Results from this testing program are expected to be published in a scientific journal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
covid-19
-
Rhea-AI Summary

On October 6, 2021, Cue Health (Nasdaq: HLTH) announced a collaboration with Google Cloud to enhance respiratory viral variant tracking and sequencing. This partnership aims to integrate real-time sequencing data and AI tools into the Cue Integrated Care Platform, improving public health responses to COVID-19 and other infectious diseases. The Cue Health Monitoring System provides rapid, at-home COVID-19 testing with results in about 20 minutes. The collaboration intends to equip health officials with predictive capabilities to manage health threats effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary

Cue Health has priced its initial public offering (IPO) at $16.00 per share, totaling $200 million in gross proceeds. A total of 12,500,000 shares will be offered, expected to begin trading on Nasdaq under the ticker HLTH on September 24, 2021. The offering is set to close on September 28, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to buy 1,875,000 more shares at the IPO price. Goldman Sachs, Morgan Stanley, and Cowen are leading the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Cue Health has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock, with details on the number of shares and price range yet to be determined. The company plans to list its stock on the Nasdaq under the ticker symbol HLTH. Goldman Sachs, Morgan Stanley, and Cowen will act as lead underwriters for the offering. A preliminary prospectus will be available once the statement becomes effective.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Cue Health Inc.

Nasdaq:HLTH

HLTH Rankings

HLTH Stock Data

6.90M
159.09M
11.57%
52.81%
0.49%
Health Information Services
Laboratory Analytical Instruments
Link
United States
SAN DIEGO